ARUPLaboratories

500 Chipeta Way – Salt Lake City, UT 84108
(800)522-2787 - www.aruplab.com
Director of Laboratories

Example Report

Patient Age/Gender: 117 years Female
Printed: 13-Dec-16 08:57:22

Procedure	Result	Units	Ref Interval	Accession	Collected	Received	Reported/ Verified
SSA 52 (Ro) (ENA) Antibody, IgG	1	AU/mL	[0-40]	16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
SSA 60 (Ro) (ENA) Antibody, IgG	13	AU/mL	[0-40]	16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
Ribonucleic Protein (U1) (ENA) Ab, IgG	1	AU/mL	[0-40]	16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
Jo-1 (Histidyl-tRNA Synthetase) Ab, IgG	7	AU/mL	[0-40]	16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
PL-12 (alanyl-tRNA synthetase) Antibody	Negative		[Negative]	16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
PL-7 (threonyl-tRNA synthetase) Antibody	Negative		[Negative]	16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
EJ (glycyl-tRNA synthetase) Antibody	**Positive** *		[Negative]	16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
OJ (isoleucyl-tRNA synthetase) Antibody	Negative		[Negative]	16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
SRP (Signal Recognition Particle) Ab	Negative		[Negative]	16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
Ku Antibody	Negative		[Negative]	16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
PM/Scl 100 Antibody, IgG	Negative		[Negative]	16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
U2 sn (small nuclear) RNP Antibody	Negative		[Negative]	16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
Fibrillarin (U3 RNP) Ab, IgG	Negative		[Negative]	16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
Mi-2 (nuclear helicase protein) Antibody	Negative		[Negative]	16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
P155/140 (TIF1-gamma) Antibody	Negative		[Negative]	16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
TIF1-gamma Antibody	See Note			16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
SAE1 (SUMO activating enzyme) Antibody	**Positive** *			16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
MDA5 (CADM-140) Antibody	See Note			16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
NXP-2 (Nuclear matrix protein-2) Ab	Negative			16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34
Myositis Panel Interpretive Data	See Note			16-301-900123	27-Oct-16 15:20:00	27-Oct-16 15:20:00	27-Oct-16 15:30:34

27-Oct-16 15:20:00   TIF1-gamma Antibody
    TIF-1 gamma positive by line immunoassay. No bands corresponding to 155/140 or 155 KDa observed by
    immunoprecipitation. Strong clinical correlation is recommended.

27-Oct-16 15:20:00   SAE1 (SUMO activating enzyme) Antibody
    SAE1 positive by line immunoassay. Bands corresponding to 90 and 40 KDa observed by
    immunoprecipitation. Profile consistent with SAE1 antibody positivity.

27-Oct-16 15:20:00   MDA5 (CADM-140) Antibody
    MDA-5 borderline by line immunoassay. No band corresponding to 140 KDa observed by immunoprecipitation.
    Strong clinical correlation recommended.

27-Oct-16 15:20:00   NXP-2 (Nuclear matrix protein-2) Ab
     NXP-2 antibody negative by line immunoassay. No band corresponding to 140 KDa observed by
    immunoprecipitation.

 27-Oct-16 15:20:00 SSA 52 (Ro) (ENA) Antibody, IgG:
INTERPRETIVE INFORMATION: SSA (Ro) (ENA) Ab, IgG

  29 AU/mL or Less .... Negative
  30 - 40 AU/mL .... Equivocal
  41 AU/mL or Greater .... Positive

SSA (Ro) antibody is seen in 70-75 percentage of Sjogren syndrome cases, 30-40% of
systemic lupus erythematosus (SLE) and 5-10 percentage of progressive systemic sclerosis
(PSS).

* Abnormal, **#** = Corrected, **C** = Critical, **f** = Footnote, **H** = High, **L** = Low, **t** = Interpretive Text, **@** = Reference Lab

ARUPLaboratories

500 Chipeta Way – Salt Lake City, UT 84108
(800)522-2787 - www.aruplab.com
Director of Laboratories

Example Report

Patient Age/Gender: 117 years Female
Printed: 13-Dec-16 08:57:22

27-Oct-16 15:20:00 SSA 60 (Ro) (ENA) Antibody, IgG:

```
29 AU/mL or Less ............. Negative
30 - 40 AU/mL ................ Equivocal
41 AU/mL or Greater ......... Positive
```

27-Oct-16 15:20:00 Ribonucleic Protein (U1) (ENA) Ab, IgG:
INTERPRETIVE INFORMATION: Ribonucleic Protein (ENA)Antibody, IgG

```
29 AU/mL or Less ............. Negative
30 - 40 AU/mL ................ Equivocal
41 AU/mL or Greater ......... Positive
```

RNP antibody is seen in 95-100 percent of mixed connective tissue disease and is
considered specific for this syndrome if other antibodies are negative; RNP is also
present in 20-30 percent of systemic lupus erythematosus and 15-25 percent of progressive
systemic sclerosis. RNP antigens also contain epitopes that are immunologically identical
to free Smith antigens, therefore, the Smith antibody response must be considered when
interpreting RNP results.

27-Oct-16 15:20:00 Jo-1 (Histidyl-tRNA Synthetase) Ab, IgG:
INTERPRETIVE INFORMATION: Jo-1 Antibody, IgG

```
29 AU/mL or less.........Negative
30-40 AU/mL..............Equivocal
41 AU/mL or greater......Positive
```

27-Oct-16 15:20:00 PM/Scl 100 Antibody, IgG:
INTERPRETIVE INFORMATION: PM/Scl-100 Antibody, IgG by
                          Immunoblot
The presence of PM/Scl-100 IgG antibody along with a positive ANA IFA nucleolar pattern
is associated with connective tissue diseases such as polymyositis (PM), dermatomyositis
(DM), systemic sclerosis (SSc), and polymyositis/systemic sclerosis overlap syndrome. The
clinical relevance of PM/Scl-100 IgG antibody with a negative ANA IFA nucleolar pattern
is unknown. PM/Scl-100 is the main target epitope of the PM/Scl complex, although
antibodies to other targets not detected by this assay may occur.

Test developed and characteristics determined by ARUP Laboratories. See Compliance
Statement D: aruplab.com/CS

27-Oct-16 15:20:00 Fibrillarin (U3 RNP) Ab, IgG:
Interpretive Information: Fibrillarin (U3 RNP) Antibody, IgG

The presence of fibrillarin (U3-RNP) IgG antibodies in association with an ANA IFA
nucleolar pattern is suggestive of systemic sclerosis (SSc). In SSc, these antibodies are
associated with distinct clinical features, such as younger age at disease onset,
frequent internal organ involvement (pulmonary hypertension, myositis and renal disease).
Fibrillarin antibodies are detected more frequently in African American patients with SSc
compared to other ethnic groups. Strong correlation with ANA IFA results is recommended.

* Abnormal, **#** = Corrected, **C** = Critical, **f** = Footnote, **H** = High, **L** = Low, **t** = Interpretive Text, **@** = Reference Lab

ARUPLaboratories

500 Chipeta Way – Salt Lake City, UT 84108
(800)522-2787 - www.aruplab.com
Director of Laboratories

Example Report

Patient Age/Gender: 117 years Female
Printed: 13-Dec-16 08:57:22

In a multi-ethnic cohort of SSc patients (n=98), U3-RNP antibodies detected by immunoblot had an agreement of 98.9 percent with the gold standard immunoprecipitation (IP) assay. Approximately 71 percent (5/7) of the borderline U3-RNP results with ANA nucleolar pattern in this cohort were IP negative.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

 27-Oct-16 15:20:00 Myositis Panel Interpretive Data:
INTERPRETIVE INFORMATION: Myositis Extended Panel

If present, myositis-specific antibodies (MSA) are specific for myositis, and may be useful in establishing diagnosis as well as prognosis. MSAs are generally regarded as mutually exclusive with rare exceptions; the occurrence of two or more MSAs should be carefully evaluated in the context of patient's clinical presentation. Myositis-associated antibodies (MAA) may be found in patients with CTD including overlap syndromes, and are generally not specific for myositis. The following table will help in identifying the association of any antibodies found as either MSAs or MAAs.

```
Antibody Specificity . . . . .  . . . . . . . MSA . . . . MAA
SSA 52 (Ro) (ENA) Antibody IgG . . . . . . . . . . . .   X
SSA 60 (Ro) (ENA) Antibody IgG . . . . . . . . . . . .   X
Ribonucleic Protein (U1) (ENA) Ab, IgG . . . . . . . .   X
Jo-1 (histidyl-tRNA synthetase) Ab, IgG  . .   X
PL-12 (alanyl-tRNA synthetase) Antibody  . .   X
PL-7 (threonyl-tRNA synthetase) Antibody . .   X
EJ (glycyl-tRNA synthetase) Antibody . . . .   X
OJ (isoleucyl-tRNA synthetase) Antibody  . .   X
SRP (Signal Recognition Particle) Ab . . . .   X
Ku Antibody  . . . . . . . . . . . . . . . . . . . . .   X
PM/SCL 100 Antibody, IgG . . . . . . . . . . . . . . .   X
U2 sn (small nuclear) RNP Antibody . . . . . . . . . .   X
Fibrillarin (U3 RNP) Ab, IgG . . . . . . . . . . . . .   X
Mi-2 (nuclear helicase protein) Antibody . .   X
P155/140 (TIF1-y) Antibody . . . . . . . . .   X
TIF1-gamma Antibody  . . . . . . . . . . . .   X
SAE1 (SUMO activating enzyme) Antibody . . .   X
MDA5 (CADM-140) Antibody . . . . . . . . . .   X
NXP-2 (Nuclear matrix proten-2) Ab . . . . .   X
```

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

* Abnormal, **#** = Corrected, **C** = Critical, **f** = Footnote, **H** = High, **L** = Low, **t** = Interpretive Text, **@** = Reference Lab

Chart ID: 11637263

Page 3 of 3